North Capital, Inc. Biomarin Pharmaceutical Inc Transaction History
North Capital, Inc.
- $106 Billion
- Q1 2025
A detailed history of North Capital, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, North Capital, Inc. holds 50 shares of BMRN stock, worth $3,164. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50Holding current value
$3,164% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BMRN
# of Institutions
635Shares Held
184MCall Options Held
2MPut Options Held
1.67M-
Black Rock Inc. New York, NY22.7MShares$1.44 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.4MShares$1.23 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.2MShares$1.15 Billion0.94% of portfolio
-
Dodge & Cox San Francisco, CA14.7MShares$933 Million0.61% of portfolio
-
Capital Research Global Investors Los Angeles, CA13MShares$822 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $11.8B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...